35 results about "Thromboxane" patented technology

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention provides a kit for detecting the curative effect of aspirin, belonging to the technical field of biology. The kit comprises a 11-dehydrogenated thromboxane B2 antibody-coated elisa plate, a horseradish peroxidase-marked 11-dehydrogenated thromboxane B2 antibody, 11-dehydrogenated thromboxane B2 standard solution, substrate color developing liquid and an interference shielding agent. The kit for detecting the curative effect of the aspirin comprises the interference shielding agent, so the interference of NaN3 in a detection sample can be effectively avoided, the generation of false negative is reduced, and the detection sensitivity and accuracy for the curative effect of the aspirin are improved.

The present invention relates to enantiomeric forms of hepoxilin analogs of Formula I-VIII, pharmaceutical compositions thereof, a method for the separation of said enantiomeric forms of hepoxilin analogs comprising applying said hepoxilin to a chiral phase HPLC column and eluting said hepoxilin with an alkane and alcohol solvent mixture. Said enantiomeric forms of hepoxilin analogs of Formula I-VIII were found to be useful in controlling the biological effects of PPAR mediated transcriptional control for the treatment of diseases such as cancer, thromboxane-mediated diseases and for modulating intracellular calcium concentration.

The present invention discloses a method for researching the pharmacodynamic relationship of various medicinal components of a compound thromboxane preparation. In the method, the mass percentage of each herbal medicine in the formula of the compound thromboxane preparation is taken as a variable, a uniform design method is used to prepare multiple difference samples with different proportions ofmedicinal materials, and at the same time, multiple missing samples of prescription medicinal materials is prepared; through pharmacodynamics research, the pharmacodynamic data of each difference sample and missing sample of the medicinal materials are obtained; and a variety of statistical methods are used to analyze the relationship between medicinal materials and efficacy in multiple samples, and the contribution, primary and secondary effects and interactions of each medicinal material are determined. The present invention discloses for the first time a method for researching the contribution, primary and secondary effects and interactions of each medicinal material in the compound thromboxane preparation, provides a basis for clarifying the compatibility rule of the scientific constituents and screening the optimal proportion of the constituents, and provides more scientific and more complete modern scientific data support for the clinical application of the compound thromboxane preparation.

The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; achemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide,3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide,3(R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide or (3R)-3-[(2S)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy]-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]actane bromide; a p38 inhibitor; a PDE inhibitor; a PPARy agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.

The invention discloses a detection kit for detecting the metabolic capability of aspirin and a preparation method of the detection kit, and the kit comprises an elisa plate coated with a monoclonal antibody of 11-dehydrothromboxane B2, a 11-dehydrothromboxane B2 competitive product, a chromogenic substrate, a stop buffer and a 11-dehydrothromboxane B2 standard solution, wherein the monoclonal antibody of 11-dehydrothromboxane B2 is a mouse monoclonal antibody, the sequence of a light chain variable region of the mouse monoclonal antibody is as shown in SEQ ID NO.2 in a sequence table, and the sequence of a heavy chain variable region of the mouse monoclonal antibody is as shown in SEQ ID NO.4 in the sequence table. The enzyme-linked immunosorbent assay kit and the method thereof have the characteristics of accuracy, high sensitivity and the like for detecting aspirin metabolism so as to judge whether a patient has aspirin drug resistance or resistance, and are not easily influenced by biochemical indexes such as creatinine and the like; and the problem of failure or poor effect of anti-platelet aggregation treatment caused by aspirin resistance of clinical patients can be greatly reduced.

The invention provides an application of thromboxane A2 synthetase inhibitor ozagrel in preparing a drug for treating smoking-induced lung cancer. It is found that the thromboxane A2 synthetase has apotential to become a novel target for treating lung cancer. Ozagrel reduce the level of thromboxane A2 by inhibiting the activity of the thromboxane A2 synthetase so as to reduce the size of lung cancer induced by smoking obviously, thereby providing a novel application path for ozagrel.

The present invention is directed to methods of inhibiting platelet aggregation, reducing serum thromboxane B2 levels, reducing systemic or cardiovascular inflammation, treating or preventing cancer and treating or preventing cardiovascular disease by oral administration of compositions containing extended release acetylsalicylic acid (ASA) or a combination of extended release ASA and immediate release ASA.

The present invention relates to a pharmaceutical composition for treatment of a disease or condition characterized by or associated with stimulation of both DPr2 and TPr signaling, said composition comprising an effective amount of a dual receptor antagonist of DPr₂ for prostaglandin D₂ and TPr for thromboxane A₂ and a pharmaceutically acceptable carrier.

The invention discloses application of a group of serum metabolic markers in predicting individual efficacy of warfarin and guiding individualized medication of the warfarin. It is found that the prediction accuracy of different drug effect samples of warfarin is significantly improved by combining serum metabolic markers guanosine, uridine, fumaric acid and thromboxine B2 with traditional indexesVKORC1 genotype, weight, serum creatinine and amiodarone for drug combination. Therefore, the group of serum metabolic markers can be used for predicting the individual efficacy of warfarin or guiding the individualized medication of warfarin in combination with the traditional indexes, and can be prepared into a kit for predicting the individual efficacy of warfarin or guiding the individualizedmedication of warfarin in combination with the traditional indexes.

The invention discloses an in-vitro evaluation model and an in-vitro evaluation method for hemostatic performance of toothpaste containing a bletilla striata extract. Evaluation indexes of the in-vitro evaluation model comprise at least one of platelet aggregation rate, cyclic adenosine monophosphate (cAMP) and thromboxane B2 (TXB2) content. The in-vitro evaluation method comprises the steps of: acquiring arterial blood of an animal, centrifuging the arterial blood, adjusting plasma concentration, and detecting absorbance OD0 when the arterial blood is blank; respectively adding a toothpaste sample containing bletilla striata extracts with different concentrations and a control sample into a pore plate filled with blood plasma, slightly oscillating the samples, incubating the samples at aconstant temperature of 37 DEG C for full reaction, and adding an adenosine diphosphate solution into the samples to induce platelet aggregation reaction; and testing plasma absorbance ODt and contentof cAMP and TXB2 when the turbidity in the reaction system changes, and calculating a platelet aggregation rate for evaluating the hemostatic performance of the toothpaste. The in-vitro evaluation model and the in-vitro evaluation method effectively reduce and avoid the usage of experimental animals, can greatly improve the working efficiency of toothpaste formula research, and reduce the in-vivotest cost.